Skip to content

Addiction: all studies

Page 67 of 859: studies 661 to 670 of 8,590, newest first. Back to the addiction overview

Research

Personality Characteristics of Adolescents with Hallucinogen, Methamphetamine, and Cannabis Dependence: A Comparative Study

Journal of Child & Adolescent Substance Abuse December 5, 2005 Glen A. Palmer, Doyle D. Daiss 14 citations

ABSTRACT A comparison of personality factors on scales of the Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-A) was conducted with a sample of adolescents referred to a residential substance abuse treatment program. A total of sixty adolescents identified with hallucinogen (n = 20), cannabis (n = 20), or methamphetamine (n = 20) as their drug of choice participated in the study....

DOI: 10.1300/j029v15n01_03 (opens in new tab) Hallucinogen Methamphetamine Clinical psychology Personality +2

Dextromethorphan psychosis, dependence and physical withdrawal.

Addiction Biology December 1, 2005 Shannon C Miller

As part of a synthesis of evidence regarding the abuse and addiction liability of dextromethorphan (DM), an over-the-counter cough medicine available in over 140 preparations, an uncommonly published case of dextromethorphan dependence (addiction) is described, with specific, rarely published complications. The individual was interviewed and several medical databases were also reviewed...

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Biological Psychiatry March 15, 2005 Deepak Cyril D'Souza, Walid Michel Abi-Saab, Steven Madonick et al.

Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders. In a 3-day, double-blind, randomized, placebo-controlled study, the behavioral, cognitive, motor, and endocrine effects of 0 mg, 2.5 mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13 stable, antipsychotic-treated...

Undoing Addiction In The Brain's Reward Sector

Chemical & Engineering News January 24, 2005 Sophie Rovner

New treatments for addiction could result from studies of ibogaine, an alkaloid derived from a West African shrub. Animal tests and anecdotal evidence in humans have indicated that ibogaine reduces cravings for alcohol and other drugs of abuse. Now, researchers at the University of California, San Francisco, have confirmed these findings in rodents and determined that ibogaine interacts with...

Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption

Journal of Neuroscience January 19, 2005 Dao‐yao He, Nancy N. H. Mcgough, Ajay Ravindranathan et al. 181 citations

Alcohol addiction manifests as uncontrolled drinking despite negative consequences. Few medications are available to treat the disorder. Anecdotal reports suggest that ibogaine, a natural alkaloid, reverses behaviors associated with addiction including alcoholism; however, because of side effects, ibogaine is not used clinically. In this study, we first characterized the actions of ibogaine on...

DOI: 10.1523/jneurosci.3959-04.2005 (opens in new tab) Full text (opens in new tab) Ventral tegmental area Neurotrophic factors Pharmacology Self-administration +3

Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC.

European Journal of Neuroscience October 2004 Guadalupe Soria, Anna Castañé, Fernando Berrendero et al.

A2A adenosine and CB1 cannabinoid receptors are highly expressed in the central nervous system, where they modulate numerous physiological processes including adaptive responses to drugs of abuse. Both purinergic and cannabinoid systems interact with dopamine neurotransmission (through A2A and CB1 receptors, respectively). Changes in dopamine neurotransmission play an important role in...

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.

Journal of Substance Abuse Treatment December 1, 2002 Evgeny Krupitsky, Andrey Burakov, Tatyana N. Romanova et al. 240 citations

Seventy detoxified heroin-addicted patients were randomly assigned to one of two groups receiving ketamine psychotherapy (KPT) involving two different doses of ketamine. The patients of the experimental group received existentially oriented psychotherapy in combination with a hallucinogenic ("psychedelic") dose of ketamine (2.0 mg/kg im). The patients of the control group received the same...

A review of chemical agents in the pharmacotherapy of addiction.

Current Medicinal Chemistry October 1, 2002 Mark S. Levi, Ronald F. Borne 70 citations

Chemical substance abuse has tormented mankind throughout history. A number of chemical approaches have been employed in an attempt to treat chemical addiction. Unfortunately, most of these have proven unsuccessful though several chemical entities have been shown to be moderately effective. The naturally occurring alkaloid ibogaine has been reported to interrupt the cravings for alcohol,...

DOI: 10.2174/0929867023368980 (opens in new tab) Full text (opens in new tab) Anti-addiction medications Substance abuse treatment Drug treatment Craving reduction +13

Ketamine dependence.

Anaesthesia and intensive care June 1, 2002 H R Pal, N Berry, R Kumar et al.

Ketamine hydrochloride is a safe and rapid-acting non-opioid, lipid soluble anaesthetic with a short elimination half-life that is used for medical and veterinary purposes. It produces a state of "dissociative anaesthesia", probably from action on N-methyl-D-aspartate (NMDA) receptors. The psychotropic effects of ketamine range from dissociation and depersonalization to psychotic experiences...

DOI: 10.1177/0310057x0203000323 (opens in new tab) Full text (opens in new tab) Ketamine Humans Substance-related disorders Anesthetics, dissociative +5

Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation.

Annals of the New York Academy of Sciences June 1, 2002 Emmanuel S Onaivi, Syed F. Ali, Sanika S Chirwa et al. 23 citations

The mapping of the human genetic code will enable us to identify potential gene products involved in human addictions and diseases that have hereditary components. Thus, large-scale, parallel gene-expression studies, made possible by advances in microarray technologies, have shown insights into the connection between specific genes, or sets of genes, and human diseases. The compulsive use of...